Patents

Approximately 60 patents in the following areas:

  1. tracheostomy
  2. treating chronic obstructive pulmonary disease
  3. treating headaches, migraines and other common ailments
  4. treating rhinitis and conjunctivitis
  5. treating trigeminal neuralgia
  6. treating jaw pain
  7. local relief of pain
  8. microbubble ultrasonic contrast agents
  9. treating chronic obstructive pulmonary disease
  10. vascular sheaths and their deployment
  11. new mattress design

Publications

WHITE PAPERS

  1. Rasor JS. Complication Rate Review: Surgical Treatment of Emphysema. Portaero, Inc. White Paper RCGPI-0311, 2011 March 6: 1-52
  2. Rasor JS. Vascular Access Advances: Vein Visualization Devices vs. Standard Unaided Venipuncture. Rasor Consulting Group. White Paper RCGAV-0510, 2010 May 17: 1-26 [AccuVein, revenues]
  3. Rasor JS. Hansen Medical Artisan Sensei Robotic Catheter System vs. Manual and Robotic Controls – Performance. Hansen Medical, Inc. White Paper RCGHM-207, 2007 December 21:1-32. [HNSN]
  4. Rasor JS. Hansen Medical Artisan Sensei Robotic Catheter System Risk vs. Benefit Assessment. Hansen Medical, Inc. White Paper, 2007 October 2: 1-6. [HNSN]
  5. Rasor JS. Important Bayesian statistics considerations. Rasor Consulting Group, Los Gatos, CA White Paper. 2007 Aug 31: 1-2.
  6. Rasor JS. Secure Wear Healthcare Products Market Analysis. Top down estimate the market size of post-surgical drain securement devices; post surgery breast binders; and post biopsy breast binders. Secure Wear Healthcare Products, Inc. White Paper, Los Angeles, CA. 2007 June 11: 1-22.
  7. Rasor, JS. Minimal clinically important difference (MCID) in residual volume/total lung capacity (RV/TLC) ratio as an endpoint using data from over 2,600 subjects. Broncus Technologies, Inc. White Paper, Mountain View, CA. 2006 May 5: 1-7. [~$111M closed]
  8. Rasor JS, Powell C. Broncus Exhale DES Risk vs. Benefit Assessment. Broncus Technologies, Inc. White Paper, Mountain View, CA. 2006 April: 1-4. [~$111M closed]
  9. Rasor, JS. Use of Sham Controls in Clinical Trials. Broncus Technologies, Inc. White Paper, Mountain View, CA. 2006 March: 1-12. [~$111M closed]
  10. Rasor, JS. Minimal clinically important difference (MCID) in residual volume using data from over 2,600 subjects. Broncus Technologies, Inc. White Paper, Mountain View, CA. 2005 Nov 28: 1-7. [~$111M closed]
  11. Rasor, JS. Validation of use of RV, FVC, and mMRC as primary endpoints in studies of treatments for emphysema and determination of the minimal clinically important difference (MCID) for RV using data from over 1,900 subjects. Broncus Technologies, Inc. White Paper, Mountain View, CA. 2005 Oct 19: 1-39. [~$111M closed]
  12. Chen I, Rasor JS, Mencin O. Market assessment report on medical device R&D outsourcing. Strategic opportunities for Innovamedica. International Business Incubator White Paper, San Jose, CA. 2004 August: 1-64
  13. Rasor JS. Walking rehabilitation/aid devices market research and competitive analysis. Hitachi Hybrid Co., Ltd. 2004 Jan 15: 1-58. [$88M revenues 2007]
  14. Rasor JS. Endoscope manipulator user survey and competitor analysis. Hitachi Hybrid Co., Ltd. 2003 Oct 15: 1-71. [$88M revenues 2007]
  15. Rasor JS, Rasor NS. CAPNIA phase II migraine study – interim results. CAPNIA, Inc. White Paper, Los Gatos, CA. 2002 Dec 31: 1-2. [CAPNIA closed ~$38M as of 2008]
  16. Rasor JS, Sun X, Sahm R, Rasor NS. Nasal carbon dioxide for treatment for migraine headache in a multicenter, randomized, double-blind, parallel- and crossover-controlled study. CAPNIA, Inc. White Paper, Los Gatos, CA. 2002 May 23: 1-10. [CAPNIA closed ~$38M as of 2008]
  17. Rasor JS. Radially expandable laproscopic access device: A controlled comparison of complication rate, effectiveness, and cost. InnerDyne Medical, Inc. White Paper, Sunnyvale CA. 1995 August: 1-10. [InnerDyne IPO <1997, acquired by Tyco 2001]
  18. Rasor JS, Antonnian F, Glick JM. Multi and single electrode electosurgery for partial meniscectomy: Comparison of depth of injury and ablation rate. ArthroCare Corporation White Paper, Sunnyvale, CA. 1995 June:1-9. [Arthrocare IPO 1996, partnered with Boston Scientific 1998]
  19. Rasor JS. The GyneSys Dx catheter system within a system: a single-visit procedure to diagnose and treat uterine and tubal disorders. OvaMed Corporation White Paper, Sunnyvale, CA. 1994 May:1-8. [OvaMed acquired by BEI Medical Systems 1996 then acquired by Boston Scientific 2002]
  20. Rasor JS. Transurethral needle ablation treatment or benign prostatic hyperplasia: Comparable results in animals and ex vivo human prostates. VidaMed, Inc. White Paper, Menlo Park, CA. 1993 Mar:1-10. [VidaMed IPO 1995, acquired by Medtronic 2002]
  21. Rasor JS. Producing a white paper: A parallel path making clinical data available before publication. Amer Med Writers H. 1991 Dec;6(4):12.
  22. Rasor JS. Landmark midline catheter performance: Analysis of an 830 catheter database. Menlo Care, Inc. White Paper, Menlo Park, CA. 1991 Jul;1(3):1-9. [Menlo Care acquired by J&J 1995]
  23. Tickner EG, Sahines TP, Rasor JS, Griffin DW, Tucker CR, Popp RL. Noninvasive assessment of pulmonary hypertension using bubble ultrasonic ringing pressure (BURP) method. National Institutes of Health Bethesda, MD. June 1976-August 1981; final Report HR-62917. [Rasor Associates, Inc spun off Berliscan acquired by Terumo Medical Corp. 2005]

BOOKS and JOURNALS

  1. DeMaria AN, Bommer W, Rasor JS, Tickner EG, Mason DT. Determination of cardiac output by two-dimensional contrast echocardiology. 1981. Hans Rijsterborgh Editor Martin Nijoff Publishers, The Hague p.245.
  2. DeMaria AN, Bommer W, Takeda P, Mason DT, Kwan OL, Rasor JS. Value and limitations of contrast echocardiography in cardiac diagnosis. Noninvasive Diagnostic Methods in Cardiology. 1983. Nobel O. Fowler Editor, F.A. Davis Company Publishers, Philadelphia, p. 167.
  3. Enzmann DR, Lyons BE, Carroll B, Placone RC, Rasor J, Britt RH, Buxton J, Wilson D. Experimental brain abscess: Enhanced sonography and pathologic correlation. AJNR Am J Neuroradiol. 1982 Jan-Feb;3(1):41-5.
  4. Carroll BA, Young SW, Rasor JS, Briller RB, Cassel DM. Ultrasonic contrast enhancement of tissue by encapsulated microbubbles. Radiology. 1982;143(3):747-50.
  5. DeMaria AN, Bommer W, Takeda P, Mason DT, Kwan OL, Rasor J. Value and limitations of contrast echocardiography in cardiac diagnosis. J Cardiography. 1983 Mar;13(1):1-13.
  6. DeMaria AN, Bommer W, Takeda P, Mason DT, Kwan OL, Rasor J. Value and limitations of contrast echocardiography in cardiac diagnosis. Cardiovasc Clin. 1983;13(3):167-79.
  7. Frizsch TH, Lange L, Shartel M, Hillman J, Rasor JS, Reiser J. The characteristics of the new safe nonlung-crossing echocontrast agent SH 454 for reproducible and homogenous opacification of blood and myocardium. Eur heart J. 1984;5(Suppl 1):197.
  8. Osterle S, Sahines T, Tucker C, Tickner EG, Rasor JS, Kernoff R, Kantrowitz N, Billingham M, Wagner L, Popp RL. A new method for assessing right-sided heart pressures using encapsulated microbubbles – A preliminary report. The Western J Med. 1985 Oct;143(4):463-8.
  9. Rasor JS. Review of catheter-related infection rates: comparison of conventional catheter materials with Aquavene. J Vascular Access Networks (JVAN). 1991 Spring;1(3):8.
  10. Rasor JS. Producing a white paper: A parallel path making clinical data available before publication. Amer Med Writers Assoc. 1991 Dec;6(4):12.
  11. Sheehan AM, Palange K, Rasor JS, Moran. Significantly improved peripheral IV catheter performance in neonates: Insertion ease, dwell time, complication rate, and costs. J Perinatology. 1992;12(4):369-76.
  12. Harwood IR, Greene LM, Kozakowski-Koch JA, Rasor JS. New peripherally-inserted midline catheter: A better alternative for intravenous antibiotic therapy in patients with cystic fibrosis. Pediatric Pulmonology. 1992;12(4):233-9.
  13. Rasor JS, Zlotta AR, Edwards SD, Schulman CC. Transurethral needle ablation (TUNA): Thermal gradient mapping and comparison of lesion size in a tissue model and in patients with benign prostatic hyperplasia. European Urology. 1993;24(3):411-4.
  14. Goldwasser B, Ramon J, Engelberg S, Ohad D, Sharkey H, Strul B, Rasor JS, Edwards SD: Transurethral needle ablation (TUNA) of the prostate using low-level radiofrequency energy: An animal experimental study. European Urology. 1993;24(3):400-5.
  15. Ramon J, Goldwasser B, Shenfeld O, Engelberg S, Rasor JS, Edwards SD: Needle ablation using radiofrequency current as a treatment for benign prostatic hyperplasia: Experimental results in ex vivo human prostate. European Urology. 1993;24(3):406-10.
  16. Schulmann CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. European Urology. 1993;24(3):415-23.
  17. Rasor JS. The Science of Friction. Special Features. Coatings Surface Treatments. Medical Device Developments. 2009 Mar;1(18):62-64. SPG Media Limited, in association with Frost Sullivan, Eucomed and the Medical Device Manufacturers Association (MDMA). Editor, Andrew Tunnicliffe. London.

ABSTRACTS

  1. Rasor JS, Hill JD, Rodvien R. A quantitative ex vivo model to evaluate thrombosis on biomaterials. ASAIO. 1975 Apr;23rd Annual Meeting.
  2. Rasor JS, Foerster J, Gee P, Vera Z, Mason DT. Vernacular fibrillation threshold decreases with moderate levels of ethanol: computer-controlled determination in the closed chest dog. The Physiologist. 1979 Aug;22(4).
  3. Foerster J, Rasor JS, Gee P, Vera Z, Mason DT. Deleterious effects of alcohol upon ventricular fibrillation threshold: computer-controlled determination in the closed chest dog. Amer Heart Assoc. 1980 Nov;52nd Scientific Sessions.
  4. Bommer W, Tickner EG, Rasor JS, Grehl T, Mason DT. Development of a new echocardiographic contrast agent capable of pulmonary transmission and left heart opacification following peripheral venous injection. Amer Heart Assoc. 1980 Nov;53rd Scientific Sessions.
  5. Bommer W, Rasor JS, Tickner EG, Takeda P, Miller L, Lee G, Mason DT, DeMaria AN. Quantitative regional myocardial perfusion scanning with contrast echocardiography. Amer College Cardiol. 1981 Mar;30th Annual Scientific Session.
  6. Armstrong WF, Kinnney EL, Mueller TM, Rasor JS, Tickner EG, Dillon JC, Feigenbaum H. Contrast echocardiography for the detection of myocardial perfusion abnormalities. Amer Heart Assoc 54th Scientific Sessions, November 1981.
  7. Tucker c, Sahines T, Rasor JS, Wagner L, Kantrwitz N, Tickner EG, Popp R. Noninvasive right ventricular pressure measurement by microbubble oscillation. Amer Hear Assoc 54th Scientific sessions, November 1981.
  8. Rasor JS, Griffin D, Bommer W, Takeda P, Mason DT, DeMaria AN. Visualization of myocardial perfusion by intraaortic injection of ultrasonic contrast agents. Amer College Cardiol 31st Annual Scientific Session, April 1982.
  9. Waltimire B, Rasor JS. Midline catheter: Virtually bloodless insertion technique and needle safety tube minimize potential for transmission of bloodborne disease. Sponsored by national Foundation for Infectious Diseases. 5th National forum on AIDS, Hepatitis, and other blood-borne diseases. Atlanta, GA, March, 1992.
  10. Rasor JS. Safety and effectiveness of a midline catheter in hospital and home care AIDS patients: A better choice than multiple peripheral restarts and central lines. Frontline Healthcare Workers: A National Conference on Prevention of Device Mediated Bloodborne Infections. Sponsored by UA Department of Health and Human Services, CDC, FDA, and OSHA. Washington DC, August 18, 1992.
  11. Rasor JS, Waltimire B. Midline catheter safety features and performance: 1,277 insertions indicate a better alternative than multiple peripheral restarts and central lines. Frontline Healthcare Workers: A National Conference on Prevention of Device Mediated Bloodborne Infections. Sponsored by US Department of Health and Human Services, CDC, FDA, and OSHA. Washington DC, August 18, 1992.
  12. Rasor JS. Safety and effectiveness of a midline catheter in hospital and home care AIDS patients: A better choice than multiple peripheral restarts and central lines. Infectious Diseases society of America Annual Meeting, Anaheim, CA, October 11, 1992.
  13. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hpyerplasia (BPH). Western Section Amer Urol Assoc, Palm Desert, CA, Nov 14-18, 1993.
  14. Schulman CC, Zlotta AR, Rasor JS, Hourriez L, Noel JC, Edwards SD. Transurethral needle ablation (TUNA): Safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia (BPH). 11th world Congress on Endourology, Florence, Italy, Oct 20-23, 1993.